CEO, JENAVALVE
WHY: Helms clinical stage medical device maker that aims to compete in the heart stent industry with Edwards Lifesciences, OC’s most valuable publicly traded company.
IN THE NEWS: Attracting heavyweight executives, directors and investors both locally and from Europe. In August, a $100M Series C financing was led by current investor Bain Capital Life Sciences as well as new investors like the Qatar Investment Authority.
QUOTABLE: “JenaValve is committed to becoming the first and only FDA-approved transfemoral transcatheter valve system indicated for symptomatic, severe aortic regurgitation, addressing an estimated multibillion-dollar U.S. market opportunity.”
